EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische Studie

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Pembrolizumab plus Chemotherapie versus Chemotherapie als perioperative Therapie bei lokal fortgeschrittenem Magen- und gastroösophagealem Übergangskarzinom: finale Analyse der randomisierten Phase-III-Studie KEYNOTE-585

Kohei Shitara iD, Sun Young Rha iD, Lucjan Wyrwicz iD, Takashi Oshima, Nina Karaseva, Mikhail Osipov, Hisateru Yasui iD, Hiroshi Yabusaki, Sergey Afanasyev iD, Young-Kyu Park, Salah Eddin Al-Batran, Takaki Yoshikawa iD und 10 weitere

Journal of Clinical Oncology · 10.10.2025 · 43 (29) · 3152-3159

DOI: 10.1200/jco-25-00486 ↗

Auf einen Blick

In KEYNOTE-585 wurde bei resezierbarem G/GEJ-Karzinom Pembrolizumab plus Chemotherapie mit Placebo plus Chemotherapie verglichen. Das Gesamtüberleben war nicht signifikant verbessert, das ereignisfreie Überleben zeigte einen Vorteil.

Fragestellung

Verbessert Pembrolizumab plus Chemotherapie als perioperative Therapie bei zuvor unbehandeltem lokal fortgeschrittenem resezierbarem Magen- oder G/GEJ-Karzinom Überleben, pathCR, Sicherheit und patientenberichtete Ergebnisse?

Methode

Randomisierte Phase-III-Studie; 1:1-Zuteilung zu neoadjuvanter und adjuvanter Pembrolizumab-plus-Chemotherapie oder Placebo-plus-Chemotherapie; Nachbeobachtung median 59,9 Monate.

Ergebnisse

Im Hauptkohorten-OS lag das mediane Überleben bei 71,8 versus 55,7 Monaten (HR 0,86; 95 %-KI 0,71–1,06). Für EFS betrug der HR 0,81 (95 %-KI 0,67–0,98). UAW Grad ≥3: 65 % versus 63 %.

Schlussfolgerung der Autor:innen

Perioperative Pembrolizumab plus Chemotherapie verschlechterte die gesundheitsbezogene Lebensqualität nicht. Die Wirksamkeits- und Sicherheitsdaten waren konsistent mit früheren Analysen.

Kernaussagen

  • OS: 71,8 vs. 55,7 Monate; HR 0,86 (95 %-KI 0,71–1,06)
  • EFS: HR 0,81 (95 %-KI 0,67–0,98)
  • Grad ≥3 UAW: 65 % vs. 63 %

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2025. Verfasst von Kohei Shitara und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Stomach Neoplasms, Esophagogastric Junction, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 12 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report results of the final analysis of overall survival (OS) and patient-reported outcomes from the phase III KEYNOTE-585 (ClinicalTrials.gov identifier: NCT03221426 ) study. Participants with previously untreated, locally advanced, resectable gastric and gastroesophageal junction (G/GEJ) cancer were enrolled into the main (n = 804) and fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT; n = 203) cohorts, and randomly assigned 1:1 to neoadjuvant and adjuvant pembrolizumab plus chemotherapy or placebo plus chemotherapy. The primary end points were pathologic complete response (pathCR) by central review, event-free survival (EFS) by investigator, OS, and safety. Patient-reported outcomes was an exploratory end point. After a median follow-up of 59.9 months (range, 39-76), median OS was 71.8 versus 55.7 months (hazard ratio [HR], 0.86 [95% CI, 0.71 to 1.06]) with pembrolizumab plus chemotherapy versus placebo plus chemotherapy in the main cohort. The EFS HR was 0.81 (95% CI, 0.67 to 0.98). Grade ≥3 drug-related adverse event rates were 65% versus 63%. Perioperative pembrolizumab plus chemotherapy did not worsen health-related quality of life versus placebo. Pembrolizumab plus chemotherapy continued to show improved outcomes in pathCR and a trend toward longer EFS versus placebo in the main and main plus FLOT cohorts. Efficacy and safety outcomes with perioperative pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in participants with untreated, locally advanced resectable G/GEJ cancer were consistent with previous analyses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedStomach NeoplasmsEsophagogastric JunctionAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansFemaleMaleMiddle AgedAgedAdultLeucovorinOxaliplatinFluorouracilDocetaxelNeoadjuvant TherapyQuality of LifeChemotherapy, Adjuvant

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabLeucovorinOxaliplatinFluorouracilDocetaxel

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea.
  • Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, Poland.
  • Kanagawa Cancer Center, Yokohama, Japan.
  • SPb SBHI Clinical Oncology Dispensary, St Petersburg, Russia.

ORCID-Profile: Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz, Hisateru Yasui, Sergey Afanasyev, Takaki Yoshikawa, Filippo Pietrantonio, Sara Lonardi, Yanfen Guan

Zitieren

APA

Shitara, K., Rha, S. Y., Wyrwicz, L., Oshima, T., Karaseva, N., Osipov, M., Yasui, H., Yabusaki, H., Afanasyev, S., Park, Y. K., Al-Batran, S. E., Yoshikawa, T., Yanez, P., Pietrantonio, F., Lonardi, S., Fang, X., Guan, Y., Valderrama, A., Leconte, P., …, & KEYNOTE-585 Investigators (2025). Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study. Journal of Clinical Oncology, 43(29), 3152-3159. https://doi.org/10.1200/jco-25-00486

Vancouver

Shitara K, Rha SY, Wyrwicz L, Oshima T, Karaseva N, Osipov M, et al. Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study. Journal of Clinical Oncology. 2025;43(29):3152-3159. doi:10.1200/jco-25-00486

BibTeX
@article{Shitara2025,
  author = {Shitara, Kohei and Rha, Sun Young and Wyrwicz, Lucjan and Oshima, Takashi and Karaseva, Nina and Osipov, Mikhail and Yasui, Hisateru and Yabusaki, Hiroshi and Afanasyev, Sergey and Park, Young-Kyu and Al-Batran, Salah Eddin and Yoshikawa, Takaki and Yanez, Patricio and Pietrantonio, Filippo and Lonardi, Sara and Fang, Xiao and Guan, Yanfen and Valderrama, Adriana and Leconte, Pierre and Bhagia, Pooja and Bang, Yung-Jue and KEYNOTE-585 Investigators, KEYNOTE-585 Investigators},
  title = {Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {29},
  pages = {3152--3159},
  doi = {10.1200/jco-25-00486}
}
Kostenlos starten →